A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association C1 - http://www.ncbi.nlm.nih.gov/pubmed/15755209?dopt=Abstract DA - 2004 Dec DO - 10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2 IS - 4 J2 - Int. J. Lepr. Other Mycobact. Dis. LA - eng N2 -A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
PY - 2004 SP - 493 EP - 500 T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association TI - The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. UR - http://ila.ilsl.br/pdfs/v72n4a13.pdf VL - 72 SN - 0148-916X ER -